[SCHEDULE 13G] TriSalus Life Sciences, Inc. SEC Filing
Utmost Group PLC reports beneficial ownership of 2,000,588 shares of TriSalus Life Sciences Inc. common stock, representing 0.0529% of the outstanding class. The filing states Utmost has sole voting and dispositive power over all reported shares and identifies Lombard International Assurance SA as a subsidiary acquired by Utmost on 30/12/2024. The disclosure explains the percentage ownership fell because TriSalus’ total outstanding shares increased to 37,838,962. The filing is a Schedule 13G indicating passive reporting under the Exchange Act rules and includes Utmost’s UK address and an authorized signature by the Group CFO dated 08/11/2025.
Utmost Group PLC dichiara la proprietà benefica di 2,000,588 azioni ordinarie di TriSalus Life Sciences Inc., pari al 0.0529% della classe in circolazione. La comunicazione indica che Utmost detiene la piena potestà di voto e il potere dispositvo su tutte le azioni riportate e identifica Lombard International Assurance SA come una controllata acquisita da Utmost il 30/12/2024. La nota spiega che la percentuale di possesso è diminuita poiché il numero totale di azioni in circolazione di TriSalus è salito a 37,838,962. Si tratta di una dichiarazione Schedule 13G, che segnala un reporting passivo secondo le norme dell’Exchange Act, e include l’indirizzo britannico di Utmost e la firma autorizzata del CFO del Gruppo datata 08/11/2025.
Utmost Group PLC informa de la propiedad beneficiaria de 2,000,588 acciones ordinarias de TriSalus Life Sciences Inc., que representan el 0.0529% de la clase en circulación. La presentación señala que Utmost tiene el poder exclusivo de voto y dispositvo sobre todas las acciones notificadas e identifica a Lombard International Assurance SA como una filial adquirida por Utmost el 30/12/2024. La divulgación explica que el porcentaje de propiedad cayó porque el total de acciones en circulación de TriSalus aumentó a 37,838,962. La presentación corresponde a un Schedule 13G que indica un reporte pasivo conforme a las normas del Exchange Act e incluye la dirección en Reino Unido de Utmost y una firma autorizada por el CFO del Grupo con fecha 08/11/2025.
Utmost Group PLC는 TriSalus Life Sciences Inc. 보통주 2,000,588주에 대한 실질적 소유를 보고했으며, 이는 발행주식의 0.0529%에 해당합니다. 제출서류는 Utmost가 보고된 모든 주식에 대해 단독 의결권 및 처분권을 보유하고 있음을 명시하고 있으며, Lombard International Assurance SA를 Utmost가 30/12/2024에 인수한 자회사로 식별합니다. 공시는 TriSalus의 총 발행주식 수가 37,838,962주로 증가함에 따라 소유 비율이 하락했다고 설명합니다. 이 제출서는 Exchange Act 규정에 따른 수동 보고를 나타내는 Schedule 13G이며 Utmost의 영국 주소와 그룹 재무책임자(CFO)의 승인 서명이 08/11/2025자로 포함되어 있습니다.
Utmost Group PLC déclare la propriété bénéficiaire de 2,000,588 actions ordinaires de TriSalus Life Sciences Inc., représentant 0.0529% de la classe en circulation. Le dépôt indique qu’Utmost exerce le pouvoir exclusif de vote et de disposition sur toutes les actions déclarées et identifie Lombard International Assurance SA comme une filiale acquise par Utmost le 30/12/2024. La divulgation explique que le pourcentage de détention a diminué car le total des actions en circulation de TriSalus est passé à 37,838,962. Il s’agit d’un Schedule 13G signifiant une déclaration passive selon les règles de l’Exchange Act et comprend l’adresse britannique d’Utmost ainsi qu’une signature autorisée du directeur financier du groupe en date du 08/11/2025.
Utmost Group PLC meldet wirtschaftliches Eigentum an 2,000,588 Stammaktien von TriSalus Life Sciences Inc., was 0.0529% der ausstehenden Klasse entspricht. Die Einreichung gibt an, dass Utmost die alleinige Stimm- und Verfügungsgewalt über alle gemeldeten Aktien besitzt und benennt Lombard International Assurance SA als Tochtergesellschaft, die Utmost am 30/12/2024 erworben hat. Die Offenlegung erklärt, dass der prozentuale Anteil gesunken ist, weil die insgesamt ausstehenden Aktien von TriSalus auf 37,838,962 gestiegen sind. Es handelt sich um ein Schedule 13G, das eine passive Meldung gemäß den Regeln des Exchange Act anzeigt, und enthält Utmosts britische Adresse sowie eine autorisierte Unterschrift des Group CFO vom 08/11/2025.
- Clear disclosure of beneficial ownership: 2,000,588 shares with sole voting and dispositive power
- Compliance with reporting rules via Schedule 13G and identification of subsidiary (Lombard International Assurance SA)
- De minimis economic/ownership impact: stake represents only 0.0529% of the class
- Dilution noted: percentage ownership fell because outstanding shares increased to 37,838,962
Insights
TL;DR: Small passive stake disclosed; ownership is non-controlling and diluted by a larger share count.
The filing shows Utmost Group PLC holds 2,000,588 shares (0.0529%), with sole voting and dispositive power, which confirms clear internal control over these holdings despite the stake being immaterial to corporate control. The note that ownership percentage decreased because outstanding shares rose to 37,838,962 is important for context: absolute share count is unchanged while relative influence fell. For investors, this is a routine disclosure under Schedule 13G rather than an activist or control filing.
TL;DR: Governance implication minimal: Utmost reports sole authority on a very small, likely passive position.
The report classifies the filer as a foreign institution and documents subsidiary involvement (Lombard International Assurance SA), indicating proper identification of the legal chain of ownership after Utmost’s acquisition of that subsidiary. Because the stake is below material thresholds and the Schedule 13G framework signals a passive intent, there are no immediate governance or control concerns for TriSalus arising from this disclosure.
Utmost Group PLC dichiara la proprietà benefica di 2,000,588 azioni ordinarie di TriSalus Life Sciences Inc., pari al 0.0529% della classe in circolazione. La comunicazione indica che Utmost detiene la piena potestà di voto e il potere dispositvo su tutte le azioni riportate e identifica Lombard International Assurance SA come una controllata acquisita da Utmost il 30/12/2024. La nota spiega che la percentuale di possesso è diminuita poiché il numero totale di azioni in circolazione di TriSalus è salito a 37,838,962. Si tratta di una dichiarazione Schedule 13G, che segnala un reporting passivo secondo le norme dell’Exchange Act, e include l’indirizzo britannico di Utmost e la firma autorizzata del CFO del Gruppo datata 08/11/2025.
Utmost Group PLC informa de la propiedad beneficiaria de 2,000,588 acciones ordinarias de TriSalus Life Sciences Inc., que representan el 0.0529% de la clase en circulación. La presentación señala que Utmost tiene el poder exclusivo de voto y dispositvo sobre todas las acciones notificadas e identifica a Lombard International Assurance SA como una filial adquirida por Utmost el 30/12/2024. La divulgación explica que el porcentaje de propiedad cayó porque el total de acciones en circulación de TriSalus aumentó a 37,838,962. La presentación corresponde a un Schedule 13G que indica un reporte pasivo conforme a las normas del Exchange Act e incluye la dirección en Reino Unido de Utmost y una firma autorizada por el CFO del Grupo con fecha 08/11/2025.
Utmost Group PLC는 TriSalus Life Sciences Inc. 보통주 2,000,588주에 대한 실질적 소유를 보고했으며, 이는 발행주식의 0.0529%에 해당합니다. 제출서류는 Utmost가 보고된 모든 주식에 대해 단독 의결권 및 처분권을 보유하고 있음을 명시하고 있으며, Lombard International Assurance SA를 Utmost가 30/12/2024에 인수한 자회사로 식별합니다. 공시는 TriSalus의 총 발행주식 수가 37,838,962주로 증가함에 따라 소유 비율이 하락했다고 설명합니다. 이 제출서는 Exchange Act 규정에 따른 수동 보고를 나타내는 Schedule 13G이며 Utmost의 영국 주소와 그룹 재무책임자(CFO)의 승인 서명이 08/11/2025자로 포함되어 있습니다.
Utmost Group PLC déclare la propriété bénéficiaire de 2,000,588 actions ordinaires de TriSalus Life Sciences Inc., représentant 0.0529% de la classe en circulation. Le dépôt indique qu’Utmost exerce le pouvoir exclusif de vote et de disposition sur toutes les actions déclarées et identifie Lombard International Assurance SA comme une filiale acquise par Utmost le 30/12/2024. La divulgation explique que le pourcentage de détention a diminué car le total des actions en circulation de TriSalus est passé à 37,838,962. Il s’agit d’un Schedule 13G signifiant une déclaration passive selon les règles de l’Exchange Act et comprend l’adresse britannique d’Utmost ainsi qu’une signature autorisée du directeur financier du groupe en date du 08/11/2025.
Utmost Group PLC meldet wirtschaftliches Eigentum an 2,000,588 Stammaktien von TriSalus Life Sciences Inc., was 0.0529% der ausstehenden Klasse entspricht. Die Einreichung gibt an, dass Utmost die alleinige Stimm- und Verfügungsgewalt über alle gemeldeten Aktien besitzt und benennt Lombard International Assurance SA als Tochtergesellschaft, die Utmost am 30/12/2024 erworben hat. Die Offenlegung erklärt, dass der prozentuale Anteil gesunken ist, weil die insgesamt ausstehenden Aktien von TriSalus auf 37,838,962 gestiegen sind. Es handelt sich um ein Schedule 13G, das eine passive Meldung gemäß den Regeln des Exchange Act anzeigt, und enthält Utmosts britische Adresse sowie eine autorisierte Unterschrift des Group CFO vom 08/11/2025.